ASH: AbbVie/Genmab Look To Stake Anti-CD20 Bispecific Claim In CLL
Data presented at the ASH conference showed high overall response and complete response rates in heavily pretreated CLL patients with Epkinly.
Data presented at the ASH conference showed high overall response and complete response rates in heavily pretreated CLL patients with Epkinly.